Healthcare & Life Sciences Sector: Trends and Upcoming Deals (September 8, 2026)

The healthcare consolidation story the market keeps telling itself is pointed at the wrong end of the sector. Ask a dealmaker where healthcare is consolidating and you will hear about hospitals, outpatient clinics and physician groups. That is where the headlines are, where the state legislatures are looking, and where most coverage models still put their weight. It is also, on our data, where middle-market companies are least likely to be preparing to transact.

Across the 83,200 middle-market healthcare, pharma and technology companies Fintent tracks, sector-level M&A Propensity sits at 0.98x — statistically indistinguishable from the broader US market. At the sector level, in other words, there is nothing to see. The entire story is the dispersion inside it: a 3.2x spread between the sub-sector preparing hardest to sell and the one preparing least, and a top end made up almost entirely of biopharma, health technology, therapy platforms and the commercialisation businesses that sell into them — not of care delivery.

Where is healthcare and life sciences deal activity actually heading in 2026?

Healthcare and life sciences deal activity is bifurcating: capital and preparation are concentrating in product and platform businesses, while care delivery — hospitals, clinics and physician practices — is transacting less, later, and more often out of distress than out of ambition. The aggregate numbers hide this completely. Fintent's sector-level M&A Propensity reads 0.98x against the US market baseline and has moved a single hundredth over four quarters. On the surface, a sector holding steady at parity.

The outside tape says the same thing in a different register. PwC's midyear read has US health services deal value resilient — roughly $29 billion across the first half of 2026 against $17 billion in the first half of 2025 — while deal volume fell, with buyers demanding proven reimbursement stability before committing (healthcaredive.com). Value up, count down is the signature of a market where a few large, high-conviction transactions carry the total and the long tail of ordinary processes has thinned out.

Where the tail has not thinned is biopharma. Reuters put Q1 2026 biopharma M&A value at $84 billion against $44.4 billion in Q1 2025, with a pace that would put the full year north of $250 billion — second only to 2019 — driven by more than $300 billion of sector revenue facing loss of exclusivity within five years, on William Blair's estimate (reuters.com). That is not a cyclical bid. It is a structural one, and it explains why the pharmaceutical end of our table sits at twice the sector baseline while the care-delivery end sits below it.

The suppression at the other end is equally structural, and it is regulatory. Stateline, citing PitchBook, counts at least 25 states that have proposed or passed private-equity healthcare transaction review legislation, with seven enacting guardrails in 2025 and California, Oregon and Rhode Island layering new mandatory deal-documentation requirements in 2026 (stateline.org). New notice regimes lengthen processes and, more importantly, deter the sponsors who would otherwise be standing up sale processes. Fierce Healthcare, on the same PitchBook dataset, projects 674 healthcare services private-equity deals for 2026 — the lowest count since 2017 against a 2018–2024 average of 903 (fiercehealthcare.com).

For a dealmaker, the practical read is this: the sector index will not tell you anything useful this year, and neither will a coverage model organised around "healthcare". Organise it around the split between businesses that sell a product or a platform and businesses that sell care, and the propensity data starts doing real work.

Which five sub-sectors are pulling ahead?

The five sub-sectors preparing hardest to transact are Digital & Marketing Agencies (2.02x), Biotechnology & Pharmaceuticals (2.02x), Therapy & Rehabilitation Services (1.52x), Healthcare IT & Software (1.45x) and Health & Wellness Services (1.42x) — all measured against the sector's own baseline. Four of the five are product, platform or programme businesses. None of them is a hospital, a clinic or a physician group.

Biotechnology & Pharmaceuticals at 2.02x on 2,932 companies is the best-evidenced call in the table, and the trend line is the interesting part. The index sits at twice the sector baseline while the eight-quarter trend is easing off a higher peak — consistent with a market where the largest processes have already found buyers and the mid-cap tail is working through. The macro case is unambiguous: Merck KGaA agreed to acquire Bio-Techne for roughly $11.3 billion on June 25, 2026 (emdgroup.com), and Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion on July 6 (crinetics.com). So what: this is the one sub-sector where a coverage model built on "who has an asset a strategic needs before 2028" beats one built on company size or ownership, because the patent cliff sets the deadline, not the sponsor's hold period.

Healthcare IT & Software at 1.45x on 2,638 companies is the cleanest risk-adjusted opportunity in the table, because the outside data confirms both the direction and the recovery. Healthcare Growth Partners counted 121 announced health IT transactions in Q2 2026, against a quarterly average near 101 across the prior two quarters, with revenue multiples recovering to 4.7x by June 30 from a 3.7x low in April (hitconsultant.net). Our eight-quarter trend for the sub-sector is rising, and the cohort reads like one keeping two doors open at once — processes that can flip between a sale and a growth round depending on where price lands. So what: approach these names early and with optionality; a rigid sell-side pitch will lose to a banker who can run either process.

Therapy & Rehabilitation Services at 1.52x on 2,202 companies is the sub-sector where our read runs ahead of the public deal record, and it is worth saying so plainly. A Brown University study published in JAMA Pediatrics found private-equity firms owned 574 autism therapy centres across 42 states as of end-2024, with roughly 80% of those acquisitions concentrated in 2018–2022 (brown.edu). That is evidence of a heavily consolidated service line, not of a fresh 2026 wave — and our own eight-quarter trend for the sub-sector dipped before recovering. The honest reading is that a first generation of platforms built in 2018–2022 is now reaching the age where sponsors exit, and preparation behaviour is showing up before the transactions do. So what: cover the platforms, not the clinics — the sellers here are sponsor-owned roll-ups approaching the end of a hold period.

Health & Wellness Services at 1.42x on 4,496 companies is the largest cohort in the top five, and strategic buyers outside healthcare are the reason. Procter & Gamble agreed to acquire the supplement brand Thorne for $3.8 billion on August 4, 2026 (bloomberg.com) — a consumer-goods balance sheet reaching into science-backed wellness, which is exactly the buyer profile that pulls a fragmented sub-sector into play. Our eight-quarter trend dipped and has turned up. So what: the buyer list for these assets is not a healthcare buyer list; if your coverage universe stops at healthcare strategics and healthcare sponsors, you will miss the bid.

Digital & Marketing Agencies ties for the highest reading in the table at 2.02x on 1,071 companies, and it is the one call where our external evidence is thin. We can point to a named, dated transaction — Indegene's October 1, 2025 acquisition of BioPharm, an Omnicom Health Group agency serving 17 of the top 25 biopharma companies, bought explicitly to build AI-driven commercialisation capability (indegene.com). What we could not find is a credible aggregate volume or multiple series for healthcare and pharma marketing agency M&A, and we are not going to manufacture one. The mechanism is plausible and consistent with the biopharma reading above — agencies whose revenue is tied to drug launches get bought when the launch pipeline reprices — but treat this as the least-corroborated row in the table. So what: worth a look, worth a discount on conviction until the public record catches up.

Sub-sector	Companies	M&A Propensity	CapRaise Propensity	8Q Trend	Read
Digital & Marketing Agencies	1,071	2.02x	0.76x	Rising	Hot — evidence thin
Biotechnology & Pharmaceuticals	2,932	2.02x	1.68x	Easing off peak	Hot
Therapy & Rehabilitation Services	2,202	1.52x	1.44x	Dipped, recovering	Sponsor exit cycle
Healthcare IT & Software	2,638	1.45x	1.42x	Rising	Hot
Health & Wellness Services	4,496	1.42x	1.35x	Dipped, recovering	Strategic buyer bid

Top 5 sub-sectors by M&A Propensity versus the sector baseline, September 2026. Sub-sectors with fewer than 1,000 tracked companies are excluded as low-signal — which is why AI & Machine Learning Solutions (1.91x on 695 companies), Compliance and Regulatory Consulting (1.80x on 338) and Manufacturing & Industrial Services (1.79x on 696) do not appear despite higher readings. CapRaise Propensity is shown for completeness.

Which five sub-sectors are cooling, and why?

The five weakest sub-sectors on deal preparation are Education & Professional Associations (0.63x), Healthcare Facilities & Clinics (0.66x), Industrial Equipment & Tools (0.74x), Pharmacy & Pharmaceutical Services (0.79x) and Healthcare Providers (0.84x). Two of them — facilities and providers — are the sub-sectors the healthcare consolidation narrative is actually about, and between them they account for 30,999 of the 83,200 companies in the sector. That is the finding worth acting on.

Healthcare Providers at 0.84x on 3,372 companies is the best-documented cooling call we have, and the mechanism is regulatory rather than cyclical. STAT, citing PitchBook's Q2 2026 Healthcare Services Report, reports private-equity physician-practice-management deals falling from a peak of 851 in 2021 to just 105 in the first half of 2026, with the segment on track to run at roughly half of 2025's count (statnews.com). Over a dozen states have added healthcare private-equity oversight in the past year, and the deterrent is as much process risk as prohibition — nobody wants to be the first through a new review regime. So what: deprioritise broad physician-practice outreach. The names still worth covering are the ones with an existing MSO structure and a sponsor already past hold-period patience, not the independent group that has never run a process.

Healthcare Facilities & Clinics at 0.66x is where our read and the recent tape genuinely disagree, and the disagreement is instructive. Kaufman Hall counted 46 announced hospital and health system transactions in 2025 against 72 in 2024, with $18.5 billion of transacted revenue and a record share — more than 43% — involving a financially distressed party (healthcaredive.com). Then hospital M&A snapped back: 22 transactions in Q1 2026, the strongest first quarter since 2020, with only 18% distressed and $14.5 billion of transacted revenue (healthleadersmedia.com). So why is our index still at 0.66x? Because the rebound is a handful of large system-level mergers and divestitures, and our cohort is 27,627 mid-sized facilities. A dozen mega-transactions move the headline without moving the base rate for the middle market. So what: do not read the hospital M&A headlines as a middle-market signal — they are a large-cap signal, and the two have decoupled.

Pharmacy & Pharmaceutical Services at 0.79x on 1,123 companies is cooling because the sub-sector is shrinking rather than selling. The National Community Pharmacists Association's 2025 Digest put independent community pharmacy count at 18,960 locations as of July 2025, down year over year, against a ten-year high in cost of goods and a ten-year low in gross profit, driven by below-cost third-party reimbursement (ncpa.org). Businesses in margin collapse do not run competitive processes; they close, or they get absorbed at distressed prices. Our eight-quarter trend for the sub-sector is falling. So what: the opportunity here is restructuring and lender coverage, not sell-side M&A.

Industrial Equipment & Tools at 0.74x on 1,351 companies is the clearest read-through from the wider macro, and it is a volume story rather than a value story. KPMG put industrial manufacturing deal count down 23.5% quarter over quarter in Q1 2026 to 1,078 transactions, with reported value distorted upward by a single outlier mega-transaction; the cited headwinds are tariffs, energy price volatility and transportation costs up 13–18% per mile (kpmg.com). Deal count is the metric that tracks preparation behaviour, and it is falling. So what: selective coverage only, and expect processes to run long where they run at all.

Education & Professional Associations at 0.63x is the weakest eligible reading in the table, and it is also the one we can least corroborate. The nearest defensible external data point is Tyton Partners' H1 2026 education deal recap, which has higher and continuing education falling to 35% of global education M&A deals from 40% a year earlier, even as total education deal volume rose 77% — a rotation away from continuing and professional education toward PreK-12 (tytonpartners.com). That is a relative shift, not a clean below-baseline signal for medical associations and CME providers specifically, and we could not find a credible series that is. The propensity read stands; the external evidence behind it is weaker than we would like. So what: treat this as a genuine cold spot but do not build a thesis on the outside data alone.

Sub-sector	Companies	M&A Propensity	CapRaise Propensity	8Q Trend	Read
Education & Professional Associations	1,376	0.63x	0.92x	Falling	Cold — evidence thin
Healthcare Facilities & Clinics	27,627	0.66x	0.55x	Rising off a low base	Cold, large-cap decoupled
Industrial Equipment & Tools	1,351	0.74x	1.17x	Falling, then flat	Cold — tariff drag
Pharmacy & Pharmaceutical Services	1,123	0.79x	1.05x	Falling	Distress, not sale processes
Healthcare Providers	3,372	0.84x	0.98x	Falling	Regulatory overhang

Bottom 5 sub-sectors by M&A Propensity versus the sector baseline, September 2026. Sub-sectors with fewer than 1,000 tracked companies are excluded as low-signal — Automation & Engineering Services (0.47x on 818 companies), Staffing & Professional Services (0.60x on 722), IT Infrastructure & Support (0.65x on 774) and Senior & Long-Term Care (0.76x on 947) all read lower or comparably but are too thin to call. CapRaise Propensity is shown for completeness.

How big is the middle-market healthcare universe we track?

The cohort behind these readings is 83,200 middle-market healthcare, pharma and technology companies, of which 75,059 carry enough signal history to be scored in scope. That is the population the sub-sector table is drawn from, and it is why the 1,000-company floor matters: a 2.58x reading on a 111-company cohort is noise, and publishing it invites a correction.

Underneath that cohort, Fintent's firmographic data tracks roughly 98,600 US companies with 25 to 1,000 employees across the healthcare and life sciences industry groupings — hospitals and health care (22,808), health and human services (20,398), health, wellness and fitness (15,293), medical practices (12,340), biotechnology research and pharmaceutical manufacturing (10,477), medical devices and equipment (8,321), health research and clinical trials (3,420), behavioural and mental health care (3,482) and veterinary services (2,012).

The size distribution is itself part of the argument. Care delivery dominates the company count and contributes least to deal preparation; the product and platform end is a fraction of the population and carries the top of the propensity table. Biotechnology & Pharmaceuticals is 2,932 companies — 3.5% of the sector cohort — and it sits joint-first on M&A Propensity. Healthcare Facilities & Clinics is 27,627 companies — a third of the cohort on its own — and sits second from the bottom.

What are we tracking right now?

431 middle-market healthcare and life sciences companies scored 50 or higher on Fintent's M&A intent score in the last month — companies whose observable behaviour looks like deal preparation before anything has been announced. By industry grouping: hospitals and health care 92, health and human services 82, health, wellness and fitness 73, medical practices 64, biotechnology and pharmaceuticals 43, medical devices and equipment 34, behavioural and mental health 17, veterinary services 14, and health research and clinical trials 12. Note what this list is and is not: it is raw pipeline volume, and volume follows cohort size. Hospitals and health care throws off the largest absolute count because it is the largest cohort, not because its base rate is strong — its propensity reading is 0.66x. The propensity index tells you where a company is unusually likely to be preparing relative to its peers; this count tells you how many names are on the board today. Use both, and do not confuse one for the other.

For the reader who wants to audit the claim rather than take it on faith.

What does "propensity" actually measure?

Propensity is a ratio, not a score: 1.00 means a cohort is preparing for a transaction at exactly the rate of its peer baseline, above 1.00 means more deal-preparation behaviour than peers, below 1.00 means less. A sub-sector at 2.02x is showing roughly twice the deal-preparation behaviour of the sector as a whole; one at 0.66x is showing about a third less.

M&A Propensity blends Fintent's Deal-Maker (M&A) and M&A intent scores — the behaviours that precede a sale process. CapRaise Propensity, the financing analogue shown alongside it in the tables above, is included for completeness only and is not what this analysis is built on.

How are these trends built from financial-intent data?

Fintent reads company-level financial-intent signals — the observable traces of banks being engaged, valuations being run, corporate law firms being retained, financing being arranged, and exit, earn-out and leveraged-buyout topics appearing in a company's orbit — then scores and dates each one and aggregates them to the sub-sector. Because the inputs are early behaviours rather than announced outcomes, the aggregate leads reported deal flow rather than following it.

Each sub-sector index is benchmarked against a peer baseline drawn from the same 83,200-company cohort, so a reading is always relative to the sector, not to the whole economy. The sector-level reading quoted at the top of this post — 0.98x M&A Propensity — is benchmarked against the US market instead.

The eight-quarter trend is the direction of travel across the trailing two years, and it is read as direction rather than as a precise slope. Sub-sectors with fewer than 1,000 tracked companies are excluded from both rankings entirely: below that floor a handful of companies can move the index several tenths, and a number that unstable is not worth publishing.

Frequently asked questions

What is healthcare M&A propensity and how is it different from deal volume?

Propensity measures how much deal-preparation behaviour a cohort is showing relative to its peers, benchmarked so that 1.00 equals parity. Deal volume counts announced transactions after the fact. A sub-sector can post high absolute volume on a weak propensity reading simply because it contains far more companies — Healthcare Facilities & Clinics is the clearest example.

Which healthcare sub-sectors have the highest M&A propensity in 2026?

Digital & Marketing Agencies and Biotechnology & Pharmaceuticals both read 2.02x against the sector baseline, followed by Therapy & Rehabilitation Services at 1.52x, Healthcare IT & Software at 1.45x and Health & Wellness Services at 1.42x. All figures are as of September 2026 and exclude sub-sectors with fewer than 1,000 tracked companies.

Why are physician practices and hospitals at the bottom of the table?

Regulation and financing conditions, not lack of interest. PitchBook data shows private-equity physician-practice-management deals falling from 851 in 2021 to 105 in the first half of 2026 as more than a dozen states added healthcare transaction review requirements. Hospital M&A rebounded in Q1 2026, but on large-system mergers that do not move the middle-market base rate.

Why are some sub-sectors excluded from the rankings?

Any sub-sector with fewer than 1,000 tracked companies is excluded as low-signal. Below that floor a small number of companies can swing the index by several tenths. AI & Machine Learning Solutions reads 1.91x on 695 companies and Compliance and Regulatory Consulting 1.80x on 338 — high readings, but too thin to publish as calls.

How early does Fintent detect M&A intent?

Across the 43 healthcare and life sciences transactions Fintent predicted between May and September 2026, the median first detectable M&A signal appeared 22.9 months before the deal was announced. These are floors rather than precise lead times, because signal history for this cohort begins in mid-2024.

How many healthcare companies are scoring high on M&A intent right now?

431 middle-market healthcare and life sciences companies scored 50 or higher on Fintent's M&A intent score in the last month, drawn from a tracked universe of roughly 98,600 US companies with 25 to 1,000 employees. The largest contributors by count are hospitals and health care, health and human services, and health, wellness and fitness.

How do I get the highest-scoring healthcare companies?

Book a demo with Fintent and we will share the 50 highest-scoring middle-market healthcare and life sciences companies from the current month at no charge, with the intent topics and signal dates behind each one, so you can judge the read for yourself before deciding whether the data belongs in your coverage process.

Sources

• Big Pharma M&A set for mega year as patent expiries drive deal urgency — Reuters, May 1, 2026 — Q1 2026 biopharma M&A value of $84bn against $44.4bn a year earlier; over $300bn of sector revenue facing loss of exclusivity within five years.
• Health services M&A is active in 2026, but uncertainty slows volume: PwC — Healthcare Dive, June 22, 2026 — US health services deal value of roughly $29bn in H1 2026 against $17bn in H1 2025, with deal volume down.
• Hospital M&A declined in 2025 amid policy uncertainty, financial stress: report — Healthcare Dive (Kaufman Hall data), January 20, 2026 — 46 announced hospital transactions in 2025 against 72 in 2024; $18.5bn transacted revenue; more than 43% involving a financially distressed party.
• From Distressed to Divestitures: Hospital M&A Roars Back in Q1 After Slow 2025 — HealthLeaders Media, 2026 — 22 hospital transactions in Q1 2026, the strongest first quarter since 2020, with 18% distressed and $14.5bn transacted revenue.
• Private equity takeovers of physician groups down by half in 2026 — STAT News (PitchBook data), August 17, 2026 — Physician-practice-management deals falling from 851 in 2021 to 105 in H1 2026.
• Projected healthcare services deal count to be lowest since 2017, PitchBook finds — Fierce Healthcare, August 19, 2026 — 674 projected healthcare services private-equity deals for 2026 against a 2018-2024 average of 903.
• As states tighten oversight, private equity's healthcare deals decline — Stateline, August 25, 2026 — At least 25 states have proposed or passed healthcare transaction review legislation; seven enacted guardrails in 2025.
• HGP July 2026 Health IT Market Review: Key Valuations and M&A Benchmarks — HIT Consultant (Healthcare Growth Partners data), July 22, 2026 — 121 announced health IT transactions in Q2 2026; revenue multiples recovering to 4.7x from a 3.7x April low.
• Private equity firms acquired more than 500 autism centers in past decade, study shows — Brown University (JAMA Pediatrics study), January 7, 2026 — 574 PE-owned autism therapy centres across 42 states as of end-2024, with about 80% of acquisitions concentrated in 2018-2022.
• P&G CEO Reveals $3.8 Billion Deal for Supplement Maker Thorne — Bloomberg, August 4, 2026 — Consumer-goods strategic buyer paying $3.8bn for a science-backed wellness brand.
• Indegene Announces Acquisition of BioPharm, an Omnicom Company — Indegene, October 1, 2025 — A named healthcare marketing agency transaction; the only verifiable data point we found for this sub-sector.
• Value over volume: Industrial M&A's Q1'26 pivot — KPMG, Q1 2026 — Industrial manufacturing deal count down 23.5% quarter over quarter to 1,078 transactions.
• NCPA Releases 2025 Digest Report — National Community Pharmacists Association, October 19, 2025 — 18,960 independent community pharmacies as of July 2025, with a ten-year high in cost of goods and a ten-year low in gross profit.
• H1 2026 Education Sector Deal Recap: The Rebound, Realized – Unevenly — Tyton Partners, H1 2026 — Higher and continuing education fell to 35% of global education M&A deals from 40% a year earlier.
• Merck KGaA agreement to acquire Bio-Techne — Merck KGaA (EMD Group), June 25, 2026 — Roughly $11.3bn life-sciences tools acquisition.
• Vertex to Acquire Crinetics Pharmaceuticals — Crinetics Pharmaceuticals, July 6, 2026 — Approximately $10bn endocrinology acquisition.